Global Blood Therapeutics - GBT Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBT, but not buy additional shares or sell existing shares.
View GBT analyst ratings or view top-rated stocks.

14 Wall Street analysts have issued 1-year target prices for Global Blood Therapeutics' stock. Their GBT share price forecasts range from $31.00 to $75.00. On average, they expect the company's share price to reach $65.42 in the next year. This suggests that the stock has a possible downside of 4.5%.
View analysts price targets for GBT or view top-rated stocks among Wall Street analysts.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.10) by $0.03. The company earned $52.05 million during the quarter, compared to the consensus estimate of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 170.37% and a negative net margin of 137.30%. Global Blood Therapeutics's revenue for the quarter was up 41.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.97) EPS.

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Global Blood Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cutler Group LLC CA (0.00%), Simplex Trading LLC (0.00%), Equitec Proprietary Markets LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and FNY Investment Advisers LLC (0.00%). Insiders that own company stock include Dawn Svoronos, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Nazila Habibizad, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends.

One share of GBT stock can currently be purchased for approximately $68.49.

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.62 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.

The company employs 457 workers across the globe.

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.